Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 18/20 | 0.71 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27856020 | 1.00 | NTRK1 (0.71) | NTRK1JAK2JAK3NUAK1 | |
| SCHEMBL27872721 | 0.96 | NTRK1 (0.73) | NTRK1JAK2JAK3NUAK1 | |
| SCHEMBL2569980 | 0.96 | NTRK1 (0.73) | NTRK1JAK2JAK3NUAK1 | |
| SCHEMBL2572107 | 0.86 | NTRK1 (0.66) | NTRK1JAK2JAK3 | |
| SCHEMBL2572103 | 0.86 | NTRK1 (0.66) | NTRK1JAK2JAK3 | |
| SCHEMBL4696037 | 0.86 | NTRK1 (0.85) | NTRK1JAK2JAK3NUAK1 | |
| SCHEMBL2570794 | 0.85 | NTRK1 (0.66) | NTRK1JAK2JAK3NUAK1 | |
| SCHEMBL5029800 | 0.85 | NTRK1 (0.66) | NTRK1JAK2JAK3NUAK1 | |
| SCHEMBL2568696 | 0.85 | NTRK1 (0.52) | NTRK1JAK2JAK3 | |
| SCHEMBL4072344 | 0.85 | NTRK1 (0.80) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383268-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2015-09-02 | — | — | EP | disclosed |
| CN-101155800-B | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB | 2012-05-23 | — | — | CN | disclosed |
| EP-2383268-A1 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | AstraZeneca AB (SE) | 2011-11-02 | — | — | EP | disclosed |
| EP-1853588-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| US-20080108669-A1 | Use 541 | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| CN-101119988-A | Chemical compound | ASTRAZENECA AB (SE) | 2008-02-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108669-A1 | Use 541 | TRPV1, P2RX3, P2RX5 | NTRK1 3837/4885JAK2 1797/4885JAK3 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.